- Details
- Rashid Sayyid and Zach Klaassen discuss The New England Journal of Medicine publication "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer." The ProtecT trial invited over 82,000 men between 50 and 69 years, and prostate cancer was diagnosed in 2,664 men, and of these men, just over 1,600 were randomized to either active monitoring, prostatectomy, or radiotherapy...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses "Inherited TP53 Variants and Risk of Prostate Cancer" comparing two cohorts: a Li-Fraumeni syndrome cohort of 163 men from 132 families and a prostate cancer cohort of 7,000 patients. This study aims to determine if gTP53 predisposes to prostate cancer, as there is no known association. Results showed that the incidence rate of prostate can...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses the publication from the JCO Precision Oncology, "Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs." In this study, nearly one in five, or 17.2%, prostate cancer patients had positive germline mutations, including relativel...
|
- Details
- Zach Klaassen discusses an article entitled "Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study" in this UroToday Journal Club discussion. The UK Genetic Prostate Cancer Study investigated the association between family history and prostate cancer outcomes, including known prognostic factors, prostate cancer-specific mortality, and all-cause mortality....
|
- Details
- Zachary Klaassen reviews a JAMA Oncology publication entitled, "Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening." This large national cohort study found that rates of PSA testing increased after the USPSTF's draft statement in 2017, reversing trends seen after earlier guidance against PSA testing for...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses the publication “Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.” This retrospective cohort study aims to assess the contemporary practice patterns regarding the use of dual-energy x-ray absorptiometry...
|
- Details
- In this UroToday Journal Club discussion, Zach Klaassen discusses a review paper entitled "Mechanisms Mitigation and Management of Urinary Toxicity from Prostate Radiotherapy." The review discusses the prevalence and difficulty of managing urinary toxicity in patients receiving pelvic radiotherapy, especially those with prostate cancer, and the importance of long-term survivorship and reducing tre...
|
- Details
- Chris Wallace and Zach Klaassen discuss updates in the 2023 NCCN Clinical Practice Guidelines in Oncology for prostate cancer. They focus on a new section of the guidelines that emphasize the importance of shared decision-making and maintaining quality of life during prostate cancer treatment. As part of the guidelines, the panel recommends baseline measures of disease-specific functions, includin...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses the publication entitled Prostate Cancer Screening Using Combination of Risk Prediction, MRI, and Targeted Prostate Biopsies, the STHLM3-MRI trial. The study performed a prospective, randomized, population-based trial among men aged 50 to 74 to evaluate various prostate cancer screening strategies. The study showed that replacing PSA with S...
|
- Details
- In this UroToday Journal Club discussion, Zach Klaassen discusses the publication "Polygenic Risk of Any, Metastatic, and Fatal Prostate Cancer in the Million Veteran Program." The publication explores the potential use of genetic risk scores in identifying individuals most at risk of developing advanced prostate cancer, particularly those who may benefit most from PSA testing and screening. The p...
|
